WAM
BCTXL

Warberg Asset Management’s BriaCell Therapeutics Warrant BCTXL Stock Holding History

Warberg Asset Management’s Portfolio BCTXL Stock Details BCTXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
159,555
+44,555
+39% +$41.2K 0.03% 129
2026
Q1 		$118K Buy
+115,000
New +$122K 0.02% 134

Other funds holding BCTXL

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Warberg Asset Management's BCTXL Position: Q2 2026 in Review

Warberg Asset Management increased its BriaCell Therapeutics Warrant (BCTXL) stake by 39% in Q2 2026, buying an estimated $41.2K and bringing the position to 159,555 shares worth $142K. The position accounts for 0.03% of the portfolio, ranked #129.

Warberg Asset Management first reported a position in BCTXL in Q1 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.

  • Warberg Asset Management held 159,555 shares of BriaCell Therapeutics Warrant worth $142K as of Q2 2026.
  • Warberg Asset Management bought 44,555 BriaCell Therapeutics Warrant shares in Q2 2026, an estimated $41.2K.
  • BriaCell Therapeutics Warrant made up 0.03% of Warberg Asset Management's portfolio in Q2 2026, its #129 holding.
  • Warberg Asset Management first reported a position in BriaCell Therapeutics Warrant in Q1 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.